Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Experience“
Suchtreffer
Begriffe & Kennungen
Abiraterone Mylan · 4.8 · Adverse reactions observed during clinical studies and post-marketing experience are listed below by frequency
Eintrag öffnenAblymico · 4.8 · Patients with mild or moderate renal impairment (creatinine clearance ≥ 30 mL/min) may experience more gastroi
Eintrag öffnenAblymico · 4.8 · Patients ≥ 65 years of age may experience more gastrointestinal effects when treated with liraglutide.
Eintrag öffnenAbnormal experience of reality
Eintrag öffnenAclasta · 4.8 · The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the fir
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy in the pivotal phase 2 studies (SG035-0003 and SG035-0004
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until la
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until la
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · From post-marketing experience with AS03-containing vaccines containing 3.75 microgram HA derived from A/Calif
Eintrag öffnenAdtralza · 4.8 · Adverse reactions observed from clinical trials and post-marketing experience are presented in Table 1 by syst
Eintrag öffnenAkeega · 4.8 · Thrombocytopenia Thrombocytopenia was reported in 20.9% of treated patients while 7.5% of patients experienced
Eintrag öffnenAldara · 4.8 · In trials with 5 times per week dosing 58% of patients experienced at least one adverse event. The most freque
Eintrag öffnenAlli (previously Orlistat GSK) · 4.5 · Based on reports from literature and post-marketing experience orlistat may potentially reduce the absorption
Eintrag öffnenAmlodipine / Valsartan Mylan · 4.8 · % of patients who experienced Valsartan (mg) peripheral oedema 0 40 80 160 320 0 3.0 5.5 2.4 1.6 0.9 2.5 8.0 2
Eintrag öffnenAmmonaps · 4.8 · In clinical trials with AMMONAPS, 56 % of the patients experienced at least one adverse event and 78 % of thes
Eintrag öffnenAmmonaps · 4.8 · In clinical trials with AMMONAPS, 56 % of the patients experienced at least one adverse event and 78 % of thes
Eintrag öffnenAmyvid · 4.8 · Adverse reactions observed during clinical studies and post-marketing experience are listed below by frequency
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The safety profile of ANORO ELLIPTA is based on safety experience with umeclidinium/vilanterol and the individ
Eintrag öffnenApixaban Accord · 4.5 · There is limited experience of co-administration with other platelet aggregation inhibitors (such as GPIIb/III
Eintrag öffnenApixaban Accord · 4.5 · There is limited experience of co-administration with other platelet aggregation inhibitors (such as GPIIb/III
Eintrag öffnen